S&P 500 component Moderna, Inc. (MRNA) climbed 4.8%, extending its rebound momentum from Monday's session. The vaccine sector broadly declined last Friday after Trump administration health officials announced plans to present claims this week to a key vaccine advisory committee under the U.S. Centers for Disease Control and Prevention (CDC) regarding alleged connections between COVID-19 vaccines and 25 pediatric deaths.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.